Biology is in the midst of a revolution. Recent advances have occurred in virtually all areas of the biological sciences. Two completely new fields of research, genomics and proteomics, have the potential to radically advance our understanding of life and transform medicine. Perspectives on these important fields of research are featured in this issue of *The Yale Journal of Biology and Medicine*.

The effort to decode the sequence of the human genome has spawned a plethora of initiatives in gene discovery and high throughput analysis of gene and protein function. Indeed, there has been a paradigm shift in biological research from the analysis of individual genes and proteins to the global analysis of thousands of genes, proteins, and metabolites simultaneously. This advance has permitted entire pathways and systems to be studied in a single research initiative and allowed more rapid, resource-effective, and fruitful investigations into human health and disease. As an example, the cost of mapping a genetic disease has been reduced more than 10-fold, thus resulting in a greater number of disease loci to be mapped.

Driving the shift to system-wide biological investigations have been amazing advances in technologies. The development of DNA and protein microarrays allowed the analysis of the expression of thousands of genes and the activities of thousands of proteins in a single experiment. Recently, the advent of new DNA sequencing technologies resulted in the first reports of complete DNA sequences of individuals as well as a variety of other advances. The first of these new technologies, 454 Sequencing™, was launched commercially in 2006 and led to myriad discoveries, including one of the first complete human genome sequences; the sequencing of Neanderthal DNA; the sequencing of a major human pathogen, *Acinetobacter baumanni*; the discovery of the large magnitude of structural variation in the human genome; the attribution of bee colony collapse disorder to a new virus; and discovery of pathogens that cause human disease. An effort is under way to sequence the genomes of 1,000 individuals from diverse parts of the world, and many companies are rushing to develop technologies striving to bring the cost of sequencing a human genome to \$1,000.

As impressive as the advances in genomics have been, equally impressive are the advances in proteomics, the study of all proteins. We now can analyze thousands of proteins at once using protein microarrays, and we can profile thousands of proteins using new techniques in mass spectrometry. These latter technologies are expected to be particularly valuable in analyzing biological samples and in the discovery of biomarkers that might be useful in the early detection of such illnesses as cancer, diabetes, and autoimmune diseases. Nearly all of the latest technologies for genomics and proteomics are available at the Keck Center or the Yale Center for Genomics and Proteomics.

The new DNA sequencing and proteomics technologies are expected to usher in an era of personal genomics. In many cases, it should be possible to help pinpoint genetic propensities for particular diseases, the nature of the genetic defect once a disease is detected, and predict the likelihood of response to particular therapies. Likewise, proteomics tools are expected to have applications for personalized medicine. Current gene- and protein-based tests utilize a limited number of markers; in the future, they will likely use hundreds, if not thousands, of markers.

In the articles herein, the reader will find descriptions of the new genomics and proteomics technologies and interviews with their inventors and other leaders in the field. These descriptions of how genomics and proteomics have helped us understand human health and disease and their future potential will give the reader key insights into the revolution ongoing in biology.
